- By ICR Secretariat
- Posted Tuesday, November 29, 2022
With Sanofi as its marketing partner, Provention Bio grabs long-awaited FDA nod for diabetes drug
https://www.fiercepharma.com/pharma/provention-bio-wins-long-awaited-fda-approval-type-1-diabetes-drug
What a long, strange trip it’s been for teplizumab, a drug developed to combat juvenile diabetes—36 years to be exact.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- 10 clinical trials to watch in the first half of 2023 19/01/2023 03:56 PM
- 'The Top Line': FDA's stance on cancer drug approval, plus this week's headlines 19/01/2023 03:55 PM
- 5 questions facing gene therapy in 2023 19/01/2023 03:53 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org